Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT06917079
What this trial is testing

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Who this might be right for
Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 665
Testing effectiveness (Phase 2)Looking for participantsNCT05288205
What this trial is testing

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12CNon-small Cell Lung CancerColorectal Cancer+1 more
Allist Pharmaceuticals, Inc. 240
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07827261
What this trial is testing

BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 36
Early research (Phase 1)Study completedNCT04959981
What this trial is testing

Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

Who this might be right for
Advanced Non-squamous Non-small-cell Lung Cancer
Erasca, Inc. 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445843
What this trial is testing

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Who this might be right for
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Novartis Pharmaceuticals 95
Early research (Phase 1)Looking for participantsNCT06983743
What this trial is testing

ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Solid Tumors
Erasca, Inc. 600
Early research (Phase 1)Study completedNCT04006301
What this trial is testing

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Who this might be right for
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more
Janssen Research & Development, LLC 10
Large-scale testing (Phase 3)Active Not RecruitingNCT06497556
What this trial is testing

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche 338
Testing effectiveness (Phase 2)Looking for participantsNCT07164170
What this trial is testing

Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Who this might be right for
Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd 86
Large-scale testing (Phase 3)Looking for participantsNCT07554339
What this trial is testing

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 310
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339839
What this trial is testing

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

Who this might be right for
NSCLC Stage IVKRAS G12C
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 42
Large-scale testing (Phase 3)Looking for participantsNCT06119581
What this trial is testing

First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
Eli Lilly and Company 1,264
Early research (Phase 1)Looking for participantsNCT06343402
What this trial is testing

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNSCLC+3 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 350
Testing effectiveness (Phase 2)Looking for participantsNCT07629960
What this trial is testing

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms+1 more
Blueprint Medicines Corporation 265
Early research (Phase 1)Looking for participantsNCT06946927
What this trial is testing

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Jemincare 72
Large-scale testing (Phase 3)Looking for participantsNCT06793215
What this trial is testing

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche 600
Testing effectiveness (Phase 2)Ended earlyNCT06024174
What this trial is testing

BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Who this might be right for
Advanced Solid Tumors
Bristol-Myers Squibb 5
Early research (Phase 1)Looking for participantsNCT07094204
What this trial is testing

Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Who this might be right for
Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more
Astellas Pharma Inc 364
Large-scale testing (Phase 3)Study completedNCT04303780
What this trial is testing

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Who this might be right for
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Amgen 345
Testing effectiveness (Phase 2)Active Not RecruitingNCT05009329
What this trial is testing

JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

Who this might be right for
NSCLCSolid Tumor
Allist Pharmaceuticals, Inc. 315
Next Page